J&J, Roche Partner Halozyme Buys Antares Pharma for $1B, Beefing Up Drug Delivery Offerings
Having struck partnerships with the likes of Johnson & Johnson, GlaxoSmithKline and Roche, Halozyme is best known for its under-the-skin drug delivery platform. Now, the company is buying into the auto-injector realm and setting out to cultivate an internal commercial team.
Halozyme has signed a deal to purchase auto-injector specialist Antares Pharma for about $960 million, or $5.6 per share, to further expand its drug delivery offerings.
Antares’ auto-injector technologies are behind several marketed products, including the Vibex device used in Teva’s generic EpiPen and generic Forteo. The deal also gives Halozyme a suite of internal commercial products and a sales team.
Read the full article at: www.fiercepharma.com
- About the Author
- Latest Posts
BioBuzz is a community led, experience focused, biotech and life sciences media and events company. BioBuzz highlights regional breaking news, industry professionals, jobs, events, and resources for business and career growth. Their weekly newsletter is subscribed to by thousands in the BioHealth Capital Region and Greater Philadelphia as the go-to for industry updates.
